Answers are grounded in this paper and cite their sources.
Retrospective analysis shows COPD is linked to shorter progression-free survival in NSCLC patients receiving osimertinib, indicating treatment challenges.
Osimertinib is one of the standard treatments for advanced EGFR -mutated non–small cell lung cancer (NSCLC). Although chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis of NSCLC patients, the impact of COPD on clinical outcomes of such patients receiving osimertinib has remained unclear. We retrospectively analyzed 93 patients with EGFR -mutated NSCLC receiving osimertinib as first-line therapy between May 2015 and February 2024. COPD was defined by spirometry as a forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio of <0.7 with a smoking history. Osimertinib efficacy including progression-free survival (PFS) was evaluated according to COPD status. Of the 93 patients, 37 (39.8%) were smokers and 17 (18.3%) had COPD. PFS was significantly shorter in all patients with COPD than in all those without COPD (median, 14.6 versus 21.2 months; P =0.0148), with a similar trend being observed among smokers (median, 14.6 versus 18.8 months; P =0.098). Multivariate analysis adjusted for clinical factors revealed that COPD was independently associated with a shorter PFS (hazard ratio, 2.00 [95% CI, 1.07–3.72]; P =0.029). Adverse events leading to treatment discontinuation (odds ratio [OR], 8.17 [95% CI, 2.23–25.55]; P =0.002) and cardiac events (OR, 6.36 [95% CI, 1.79–20.39]; P =0.007) were more frequent in the COPD group. Coexisting COPD was associated with a shorter PFS for osimertinib and a higher risk of treatment discontinuation, particularly as a result of an increased frequency of cardiac events. Careful cardiac monitoring and optimized management of comorbidities are warranted to improve outcomes.
No takes yet. Share an insight, caveat, or question.
Ishikawa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: